Other genes, such as ETV4, ETV5, CCND1, EPHA2, and EPHA4, also play a role in activating the MAPK pathway, promoting tumor resistance to MEKi (Chesnokov et al., 2022). This evidence concerns the gene EPHA2 and neoplasm.